NCT06494774View on ClinicalTrials.gov

A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

November 13, 2024

Study Completion Date

November 13, 2024

Conditions
Healthy
Interventions
DRUG

BI 1815368

BI 1815368

DRUG

Placebo matching BI 1815368

Placebo matching BI 1815368

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06494774 - A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men | Biotech Hunter | Biotech Hunter